Posted by Michael Wonder on 04 Nov 2021
Libtayo (cemiplimab) approved in Canada for locally advanced basal cell carcinoma patients
29 October 2021 - The approval is based on data from the open-label, multi-center, non-randomised study 16201.
Libtayo (cemiplimab) is now approved in Canada for the treatment of adults with locally advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor.
